MTOR and non-small cell lung carcinoma: Antroquinonol has been demonstrated to exhibit inhibitory effects on non-small cell lung cancer (NSCLC), as well as human pancreatic cancer, PANC-1 and ASPC-1, via the PI3K/Akt/mTOR pathway [72].